Galectin-3 Binding Protein, Depression, and Younger Age Were Independently Associated With Alexithymia in Adult Patients With Type 1 Diabetes

Eva O. Melin 1,2*, Ralph Svensson 3, Jonatan Dereke 1 and Magnus Hillman 1†

1 Diabetes Research Laboratory, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden, 2 Region Kronoberg, Department of Research and Development, Växjö, Sweden, Department of Psychology, Linnaeus University, Växjö, Sweden

Aims: Alexithymia has been linked to cardiovascular disease. The aim was to explore whether the immuno-inflammatory variables galectin-3 binding protein (Gal3BP), soluble (s)CD163 and galectin-3 were independently associated with alexithymia, while controlling for known risk factors for cardiovascular disease, such as depression, anxiety, impaired glycemic control, obesity, smoking, and physical inactivity in patients with type 1 diabetes (T1D).

Methods: Cross-sectional design. The participants were consecutively recruited from one diabetes out-patient clinic. Alexithymia, depression and anxiety were assessed by self-report instruments. Blood samples, anthropometrics, and blood pressure were collected, supplemented with data from electronic health records. High Gal3BP was defined as ≥3.3 µg/ml, high sCD163 as ≥0.6 µg/ml, high galectin-3 as ≥2.6 ng/ml, impaired glycemic control as HbA1c >70 mmol/mol (>8.6%) and abdominal obesity as waist circumference ≥1.02 m for men and ≥0.88 m for women.

Results: Two hundred and ninety two patients participated (men 56%, aged 18–59 years, alexithymia prevalence 15%). Patients with alexithymia had higher prevalence of depression (34 vs. 6%, p < 0.001), anxiety (61 vs. 30%, p < 0.001), high Gal3BP levels (39 vs. 17%, p = 0.004), high HbA1c levels (46 vs. 24%, p = 0.006), and abdominal obesity (29 vs. 15%, p = 0.045). Depression [adjusted odds ratio (AOR) 6.5, p < 0.001], high Gal3BP levels (AOR 2.4, p = 0.035), and age (AOR 0.96, p = 0.027) were independently associated with alexithymia. Abdominal obesity (AOR 4.0, p < 0.001), high Gal3BP levels (AOR 2.8, p = 0.002), and depression (AOR 2.9, p = 0.014) were associated with high HbA1c. Abdominal obesity and anxiety were associated [Crude odds ratio (COR) 2.4, p = 0.006].
Conclusions: T1D patients with alexithymia had higher prevalence of high Gal3BP levels, depression, impaired glycemic control, anxiety, and abdominal obesity, which are known risk factors for cardiovascular disease. Only high Gal3BP levels, depression, and younger age were independently associated with alexithymia in adult patients with T1D.

Keywords: alexithymia, depression, galectin-3, galectin-3 binding protein, glycemic control, obesity, sCD163, type 1 diabetes

INTRODUCTION

Alexithymia literally denotes “no words for feelings.” Alexithymia is a state or personality trait characterized by limited ability to identify and describe feelings, and to distinguish between sensations in the body caused by emotional arousal and sensations of other origins (1–3). An externally oriented cognitive style and constricted imaginal processes are other features of alexithymia (1–3). Alexithymia is also characterized by inflexible emotion regulation with inadequate emotional reactivity, prolonged emotional states and failed habituation (4). Emotional neglect, physical or sexual abuse during childhood, as well as neuropsychiatric and genetic disturbances may cause alexithymia (5–7).

Alexithymia has been linked to increased cardiovascular disease and mortality (8, 9), type1 diabetes (T1D) (10), obesity (11, 12), higher blood pressure and dyslipidaemia (13), depression (9, 14–16), and anxiety (17, 18). Increased baseline levels of sympathetic activity and disturbances of the hypothalamo-pituitary-adrenal (HPA) axis have been demonstrated in persons with alexithymia (2, 3). Both the increased chronic sympathetic arousal and the disturbances of the HPA axis make persons with alexithymia highly vulnerable to chronic stress conditions (2, 3). It has been suggested that alexithymia impacts the function of the human immune system both through the sympathetic overreactivity and the activation of the HPA axis (2, 3). Disturbances of the immune system, involving monocytes and macrophages, contribute to the development of atherosclerosis and cardiovascular disease (19–25). Galectin-3 binding protein (Gal3BP) is a macrophage scavenger receptor which, while activated, induces a number of pro-inflammatory cytokines (21). Gal3BP, which is also known as Mac-2BP, LGALS3BP or 90K, is part of the innate immune system (26). Increased plasma levels of Gal3BP have been linked to metabolic disturbances (27), to recurrent angina/myocardial infarction (22), and to cardiovascular and all-cause mortality (21). CD163 is a macrophage and monocyte expressed scavenger receptor (28). After ectodomain shedding, the extracellular portion of CD163 circulates in blood as a soluble protein (sCD163) (29). The sCD163 levels increase during macrophage activation (29). Increased sCD163 levels have been linked to acute coronary syndrome (23). Galectin-3 is a beta-galactoside-binding lectin involved in several inflammatory processes (30). Galectin-3 has been linked to depression (31, 32), heart failure (24), coronary artery disease (25), and all-cause mortality (22).

Other factors previously linked to cardiovascular disease and mortality are metabolic disturbances (13, 33, 34), T1D (35), physical inactivity (36), smoking (37), depression (38), and anxiety (39). Depression has also been linked to several inflammatory, metabolic and HPA-axis disturbances (15, 31, 32, 40–44), which is also the case for obesity, smoking and physical inactivity (15, 36, 37, 42, 43). T1D is an auto-immune disorder characterized by insulin-deficiency (46), which is accompanied by several metabolic disturbances (33, 34).

As alexithymia previously has been linked to cardiovascular disease and mortality (8, 9), we wanted to explore whether selected known risk factors for cardiovascular disease and mortality were directly or indirectly linked with alexithymia in patients with T1D. The main aim was to explore whether the immuno-inflammatory variables Gal3BP, sCD163, and galectin-3 were independently associated with alexithymia controlling for depression, anxiety, metabolic and life style factors, medication, and cardiovascular complications.

MATERIALS AND METHODS

Participants and Study Design

The study has a cross sectional design and included 292 (69%) patients out of 424 eligible patients with T1D (15). Inclusion criteria were T1D of ≥1-year duration, in patients 18–59 years of age. Exclusion criteria were pregnancy, severe somatic and psychiatric disorders such as cancer, hepatic failure, end-stage renal disease, Cushing’s disease, severe autoimmune disorders, psychotic disorders such as schizophrenia, bipolar disorder, severe personality disorders, severe substance abuse, cognitive deficiency (due to stroke, dementia, or intellectual disability), or inadequate knowledge of the Swedish language. No patients used antipsychotic drugs (15). The patients were consecutively recruited during a 9-month period, from 25 March 2009 to 28 December 2009, from the largest out of two hospital diabetes outpatient clinics in Region Kronoberg, Sweden. The catchment population was 125,000. Self-report questionnaires were used to assess alexithymia, depression and anxiety. Blood samples, anthropometrics, and blood pressure were collected, supplemented with data from electronic health records (12, 15, 31, 40–42, 47–49). The study was performed in accordance with the Declaration of Helsinki, and was approved by the Regional Ethical Review Board of Linköping University, Linköping (Registration...
no. M120-07, T89-08). All participants provided written informed consent.

Definitions of Alexithymia, Depression, and Anxiety
Alexithymia was assessed by Toronto Alexithymia Scale-20 items (TAS-20) and alexithymia was defined as ≥ 61 points (3, 8, 9, 11, 12, 14, 15, 17, 18, 50–52). TAS-20 has a three-factor structure with three subscales, “Difficulty Identifying Feelings” (DIF), “Difficulty Describing Feelings” (DDF) and “Externally Oriented Thinking” (EOT) (50, 51). The alexithymia characteristic of constricted emotional processes is not elucidated by TAS-20.

Depression and anxiety were assessed by Hospital Anxiety and Depression Scale (HADS). Depression was defined as HADS—the depression subscale (HADS—D) ≥ 8 points and anxiety as HADS—the anxiety subscale (HADS—A) ≥ 8 points (15, 31, 42, 53).

Definitions of Abdominal and General Obesity, Severe Hypoglycaemia Episodes, and Cardiovascular Complications
Abdominal obesity was defined as waist circumference (WC) ≥ 1.02 m for men and as WC ≥ 0.88 m for women, and general obesity was defined as BMI ≥ 30 kg/m² for both sexes. A severe episode of hypoglycaemia was defined as hypoglycaemia to such a degree that the patient needed help from another person. Severe hypoglycaemia episodes occurring during a period of 6 months prior to inclusion were included. Cardiovascular complications were defined as cardiac failure, ischemic heart disease, stroke, or transient ischemic attack (TIA) (15).

Smoking and Physical Activity
Smokers were defined as having smoked any amount of tobacco during the last year (15). There were four categories of physical activity including at least 30 min of moderate activity: less than once a week, 1–2 times a week, 3–5 times a week, and daily.

Blood Pressure, Antihypertensive Drugs, and Indications for Treatment of Hypertension
Blood pressure was measured in the sitting position by a nurse. The antihypertensive drugs which were used by the patients were previously described (41). The use of antihypertensive drugs was dichotomized into users and non-users (41). Indications for antihypertensive drugs were systolic blood pressure > 130 mm Hg and/or diastolic blood pressure > 80 mm Hg (41).

Serum-Lipids, Lipid-Lowering Drugs, and Indications for Treatment of Hyperlipidemia
Serum-lipids were collected after an overnight fast. Lipid lowering drugs were HMG CoA-reductase inhibitors, and the use of lipid lowering drugs was dichotomized into users and non-users (41). Indications for lipid lowering drugs were total cholesterol (TC) > 4.5 mmol/l (> 1.74 mg/dl) and/or LDL-cholesterol > 2.5 mmol/l (> 97 mg/dl) (41).

Insulin
Patients used either multiple daily insulin injections (MDII) or continuous subcutaneous insulin infusion (CSII).

Antidepressants
The antidepressants which were used by the patients were previously described (41). The use of antidepressants was dichotomized into users and non-users.

Biochemical Analyses
Plasma levels of Gal3BP, sCD163 and galectin-3 were measured using commercially available DuoSet enzyme linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, Minnesota, USA) and optimized for human plasma. The analyses were run according to the manufacturer’s instructions (31, 47, 48). For the Gal3BP, sCD163, and galectin-3 analyses the samples were diluted 1:4,000, 1:2, and 1:200, and the intra-assay coefficients were 3.9, 4.3, and 2%, respectively. All samples were run as duplicates. High levels of Gal3BP were defined as ≥ 33 µg/ml (≥ 80th percentile) (47), high levels of sCD163 as ≥ 0.6 µg/ml (≥ 80th percentile) (48), and high levels of galectin-3 were defined as ≥ 2.6 ng/ml (≥ 85th percentile) (31).

HbA1c [mmol/mol (%)], serum-lipids (mmol/l), and creatinine (µmol/l) were collected. High levels of HbA1c were defined as > 70 mmol/mol (> 8.6%). Methods used for the biochemical analyses and the intra-assay coefficients of variation for each of these variables were previously described (41).

Statistical Analysis
Analysis of data distribution using histograms revealed that age, diabetes duration, Gal3BP, sCD163, galectin-3, triglycerides, systolic, and diastolic BP, were not normally distributed. Data were presented as median [quartile (q), q5; min–max], and analyses were performed with Mann-Whitney U test. Fisher’s Exact Test (two-tailed) and Linear-by-linear association were used to analyse categorical data, and data were presented as N (%).

Medians and prevalence rates for the variables included in the study were compared between patients with and without alexithymia. Variables where these comparisons showed P < 0.10, and sex, age, and cardiovascular complications independent of P-values, were included in the further analyses. Crude odds ratios (CORs) for these variables were calculated with alexithymia as dependent variable. Variables with P < 0.10 for the CORs, and age and sex independent of P-values, were entered into multiple logistic regression analysis (Backward: Wald) with alexithymia as dependent variable in three separate models, and with HbA1c > 7.0 mmol/mol as dependent variable in one model, and with cardiovascular complications as dependent variable in one model (54), The Hosmer and Lemeshow test for goodness-of-fit and Nagelkerke R² were used to evaluate each multiple logistic regression analysis model. ROC analyses were performed.
TABLE 1 | Baseline characteristics compared between 44 T1D patients with and 248 T1D patients without alexithymia.

| All patients | Alexithymia | P-value
|--------------|-------------|--------|
| N            | 292         | 44     | 248   |
| Age (years)  | (18–59)     | 38 (27, 51) | 42 (32, 51) | 0.26 |
| Diabetes duration (years) | (1–55) | 18 (9, 24) | 20 (11, 31) | 0.087 |
| Sex | | | |
| Women | 130 (44) | 24 (54) | 142 (57) | 0.19 |
| Men | 162 (56) | 20 (46) | 106 (43) |
| Depression | 30 (10) | 15 (34) | 15 (6) | <0.001 |
| Anxiety | 101 (35) | 27 (61) | 74 (30) | <0.001 |
| Abdominal obesity | 49 (17) | 12 (29) | 37 (15) | 0.045 |
| Anxiety and abdominal obesity combinations | | | |
| Anxiety/abdominal obesity combined | 25 (9) | 9 (21) | 16 (6.5) | 0.001 |
| Anxiety only | 72 (25) | 16 (38) | 56 (23) |
| Abdominal obesity only | 24 (8) | 7 (3) | 21 (8.5) |
| No anxiety/no abdominal obesity | 165 (58) | 14 (33) | 151 (62) |
| General obesity | 36 (12) | 9 (21) | 27 (11) | 0.079 |
| Systolic blood pressure (mm Hg) | (90–160) | 120 (110, 130) | 120 (110, 130) | 0.75 |
| Diastolic blood pressure (mm Hg) | (55–100) | 70 (70, 78) | 70 (70, 75) | 0.59 |
| Hypoglycemia (severe episodes) | 13 (4) | 2 (4) | 11 (4) | <0.99 |
| Smoking | 28 (10) | 6 (15) | 22 (9) | 0.26 |
| Physical inactivity | | | |
| daily | 99 (38) | 14 (35) | 85 (36) | 0.84 |
| 3–5 times/week | 86 (31) | 16 (40) | 70 (30) |
| 1–2 times/week | 59 (22) | 4 (10) | 55 (23) |
| <1 time/week | 31 (11) | 6 (15) | 25 (11) |
| Continuous subcutaneous insulin infusion | 27 (9) | 1 (2) | 26 (10) | 0.095 |
| Antidepressants | 23 (8) | 6 (14) | 17 (7) | 0.13 |
| Lipid lowering drugs | 135 (46) | 21 (48) | 114 (46) | 0.87 |
| Antihypertensive drugs | 97 (33) | 15 (34) | 82 (33) | >0.99 |
| Cardiovascular complications | 10 (3) | 3 (7) | 7 (3) | 0.18 |

Data are presented as (min-max) or N (%). *Mann-Whitney U test unless indicated, data are presented as median (q1, q3). **Fisher's Exact test. Missing values (N): |a| 6; |b| 2; |c| 17. |d| Linear—by linear association.

After log transformation (Lg10) of Gal3BP, multiple linear regression analysis (Backward) was performed with Gal3BP (Lg10) as dependent variable and with alexithymia, depression, and anxiety as independent variables. Bivariate and partial correlation analyses were performed. Pearson correlation coefficients, collinearity tolerance coefficients and variance inflation factor (VIF) coefficients were calculated. Confidence intervals (CIs) of 95% were used. P < 0.05 was considered statistically significant. SPSS® version 25 (IBM, Chicago, Il, USA) was used.

RESULTS

Baseline characteristics were compared between 44 (15%) T1D patients with and 248 (85%) T1D patients without alexithymia in Table 1. Comparisons showed that the patients with alexithymia compared to the patients without alexithymia had 5.7 times higher prevalence of depression (34 vs. 6%, p < 0.001), twice as high prevalence of anxiety (61 vs. 30%, p < 0.001), 1.9 times higher prevalence of abdominal obesity (29 vs. 15%, p = 0.045), and 3.2 times higher prevalence of combined anxiety and abdominal obesity (21 vs. 6.5%).

Results from the biochemical analyses are presented in Table 2. Comparisons showed that the patients with alexithymia compared to the patients without alexithymia had 2.3 times higher prevalence of high Gal3BP (39 vs. 17%, p = 0.004), 1.7 times higher prevalence of high sCD163 (30 vs. 18%, p = 0.095), and 1.9 times higher prevalence of high HbA1c (>70 mmol/mol) (46 vs. 24%, p = 0.006). The patients with alexithymia did not have higher prevalence of high galectin-3, but had higher median galectin-3 levels (p = 0.005).

Associations with alexithymia are presented in Table 3 for three models. Model 1: depression [adjusted odds ratio (AOR) 6.5, p < 0.001], age (AOR 0.96, p = 0.027), and high Gal3BP levels (≥3.3 µg/ml) (AOR 2.4, p = 0.035), were associated with alexithymia. Model 2: depression (AOR 6.6, p < 0.001), combined anxiety and abdominal obesity (AOR 4.9, p = 0.004), age (AOR 0.96, p = 0.028), and high Gal3BP levels (≥3.3 µg/ml) (AOR 2.4, p = 0.039), were associated alexithymia. Model 3: depression (AOR 5.8, p = 0.001), Gal3BP (per µg/ml) (AOR 1.6,
Table 2: Results from biochemical analyses compared between 44 T1D patients with and 248 T1D patients without alexithymia.

|                        | All patientsa | Alexithymia |
|------------------------|---------------|------------|
|                        | Yes | No | P-valueb |
| N                      | 292 | 44 | 248 |
| Gal3BP (µg/ml)a        | (0.8–8.9) | 2.8 (2.3, 4.2) | 2.2 (1.7, 2.9) | < 0.001 |
| High Gal3BP (>3.3 µg/ml)a | 59 (21) | 17 (39) | 42 (17) | 0.004d |
| sCD163 (µg/ml)a        | (0.2–1.9) | 0.5 (0.4, 0.6) | 0.4 (0.3, 0.5) | 0.084 |
| High sCD163 (>0.6 µg/ml)a | 57 (20) | 13 (30) | 44 (18) | 0.096d |
| Galectin-3 (ng/ml)      | (0.001–100.0) | 1.4 (0.8, 2.2) | 0.9 (0.5, 1.6) | 0.006 |
| High Galectin-3 (>2.6 ng/ml) | 42 (15) | 9 (20) | 33 (14) | 0.25d |
| HbA1c (mmol/mol)        | (25–110) | 68 (66, 78) | 62 (54, 70) | 0.007 |
| (%)                    | (4.4–12.2) | 8.4 (7.3, 9.3) | 7.8 (7.1, 8.5) | 0.87 |
| HbA1c > 70 mmol/mol (> 8.6%) | 80 (27) | 20 (48) | 60 (24) | 0.006d |
| Total cholesterol (mmol/l) | (2.1–10.9) | 4.6 (4.0, 5.4) | 4.6 (4.1, 5.2) | 0.58 |
| LDL-cholesterol (mmol/l) | (0.6–8.3) | 2.8 (2.4, 3.6) | 2.8 (2.4, 3.3) | 0.87 |
| Triglycerides (mmol/l)  | (0.1–5.9) | 0.9 (0.6, 1.8) | 0.9 (0.7, 1.2) | 0.23 |
| HDL-cholesterol (mmol/l) | (0.3–2.7) | 1.4 (1.2, 1.7) | 1.5 (1.3, 1.8) | 0.060 |
| S-Creatinine (µmol/l)   | (28–162) | 70 (64, 76) | 70 (61, 78) | 0.97 |

aData are presented as (min-max).
bMann-Whitney U test unless otherwise indicated, data are presented as median (q1, q3).
Missing value: 7. Fisher’s Exact Test. Missing values: 5; 19; 13.

p = 0.002), combined anxiety and abdominal obesity (AOR 5.1, p = 0.004), and age (AOR 0.96, p = 0.034), were independently associated with alexithymia.

The TAS-20 subscale DIF was correlated with Gal3BP (Pearson Correlation coefficient 0.136, p = 0.022), but not DDF (p = 0.55) or EOT (p = 0.66).

The ROC analyses showed that the area under the curve (lower bound-upper bound) was for alexithymia and Gal3BP 0.68 (0.59–0.77) (p < 0.001). For the chosen cut-off value, Gal3BP ≥3.3 µg/ml, the specificity was 0.85 and the sensitivity was 0.36. The area under the curve for depression and Gal3BP was 0.61 (0.50–0.71) (p = 0.054).

When alexithymia, depression and anxiety were tried against Gal3BP (Lg10), the analyses showed that alexithymia was associated with Gal3BP (Lg10) (unstandardized B coefficient 0.122, p < 0.001), which was neither the case for depression nor for anxiety (p = 0.89 and 0.94, respectively).

In bivariate correlations analyses, the Pearson Correlation coefficients were for Gal3BP and alexithymia 0.330 (p < 0.001), and for Gal3BP and depression 0.125 (p = 0.035). When partial correlation analysis was performed, controlling for alexithymia, the correlation coefficient for Gal3BP and depression was 0.044, (p = 0.46).

Collinearity analyses were calculated with alexithymia as dependent variable, and the included independent variables were age, diabetes duration, sex, depression, anxiety, abdominal obesity, Gal3BP, sCD163, HbA1c, and HDL. The results of the collinearity analyses showed that the collinearity tolerance coefficients were all ≥0.67 and the VIF coefficients were all ≤1.49.

Associations with high HbA1c (>70 mmol/mol) are presented in Table 4. Abdominal obesity (AOR 4.0, p < 0.001), high Gal3BP levels (AOR 2.8, p = 0.002), and depression (AOR 2.9, p = 0.014) were independently associated with high HbA1c.

Abdominal obesity and anxiety were associated [COR (CI) 2.4 (1.3–4.5), p = 0.006]. There were neither any association between abdominal obesity and depression [COR (CI) 1.3 (0.5–3.4), p = 0.59] nor between abdominal obesity and high Gal3BP [COR (CI) (1.1 (0.5–2.4), p = 0.77).

Median (q1, q3) (µg/ml) Gal3BP was 3.1 (2.5, 4.0) for 10 persons with cardiovascular complications, and 2.3 (1.8, 3.0) (p = 0.050) for 275 patients without cardiovascular complications. Associations with cardiovascular complications were in univariate analyses significant for depression [COR (CI) 6.6 (1.7–24.8), p = 0.005] and for Gal3BP (per µg/ml) [COR (CI) 1.5 (1.0–2.2), p = 0.039], but not for alexithymia [COR (CI) 2.5 (0.6–10.1), p = 0.19]. In multivariate analyses depression remained significantly associated with cardiovascular complications [AOR (CI) 5.4 (1.4–21.1), p = 0.016], but not Gal3BP [AOR (CI) 1.4 (0.9–2.1), p = 0.11].

DISCUSSION

Main Findings

The main findings of this study of 292 adult patients with T1D were that high Gal3BP levels, depression and younger age were independently associated with alexithymia. Abdominal obesity, anxiety and high HbA1c levels (>70 mmol/mol) were associated with alexithymia in univariate analyses. Abdominal obesity was only in combination with anxiety associated with alexithymia in multivariate analyses. Furthermore, high HbA1c levels were not independently associated with alexithymia though high HbA1c levels were associated with three different variables, abdominal obesity, high Gal3BP levels and depression, see Figure 1. The
### TABLE 3 | Associations with alexithymia in 292 T1D patients explored for three different models.

|                      | Alexithymia | Model 1 | Model 2 | Model 3 |
|----------------------|-------------|---------|---------|---------|
|                      | COR (95% CI) | P-value | AOR (95% CI) | P-value | AOR (95% CI) | P-value | AOR (95% CI) | P-value |
| Age (per year)       | 0.98 (0.96–1.01) | 0.21    | 0.96 (0.93–1.00) | 0.027 | 0.96 (0.93–1.00) | 0.028 | 0.96 (0.93–1.00) | 0.034 |
| Diabetes duration (per year) | 0.98 (0.95–1.003) | 0.079    | 0.98 (0.95–1.02) | 0.42 | 0.98 (0.95–1.02) | 0.42 | 0.98 (0.95–1.02) | 0.43 |
| Sex (women)          | 1.6 (0.8–3.1) | 0.15    | 0.8 (0.4–2.0) | 0.69 | 0.8 (0.4–2.0) | 0.69 | 0.7 (0.3–1.6) | 0.41 |
| Depression           | 8.0 (3.6–18.1) | < 0.001 | 6.5 (2.4–17.4) | < 0.001 | 6.6 (2.4–17.9) | < 0.001 | 5.8 (2.1–16.1) | 0.001 |
| Anxiety              | 3.7 (1.9–7.3) | < 0.001 | 2.0 (0.9–4.5) | 0.094 | – | – | – | – |
| Abdominal obesity    | 2.2 (1.1–4.8) | 0.037    | 2.4 (1.0–5.8) | 0.050 | – | – | – | – |
| Anxiety/abdominal obesity combinations | – | – | – | | – | – | – | – |
| Anxiety and abdominal obesity combined | 6.1 (2.3–16.2) | < 0.001 | – | – | 4.9 (1.6–14.6) | 0.004 | 5.1 (1.7–15.4) | 0.004 |
| Anxiety only         | 3.1 (1.4–6.7) | 0.005    | – | – | 1.9 (0.7–4.8) | 0.18 | 2.2 (0.9–5.9) | 0.102 |
| Abdominal obesity only | 1.5 (0.4–5.8) | 0.52    | – | – | 2.2 (0.5–8.7) | 0.28 | 1.8 (0.4–7.6) | 0.39 |
| No anxiety/no abdominal obesity | 1 | – | – | 1 | – | 1 | – | – |
| Gal3BP (per µg/ml)   | 1.6 (1.3–2.1) | < 0.001 | – | – | – | – | 1.6 (1.2–2.1) | 0.002 |
| High Gal3BP (≥ 3.3 µg/ml) | 3.0 (1.5–6.0) | 0.002    | 2.4 (1.1–5.4) | 0.035 | 2.4 (1.0–5.4) | 0.039 | – | – |
| sCD163 (per µg/ml)   | 2.2 (0.6–7.9) | 0.23    | – | – | – | – | – | – |
| High sCD163 (≥0.6 µg/ml) | 2.0 (1.0–4.1) | 0.068    | 1.4 (0.6–3.4) | 0.43 | 1.4 (0.6–3.4) | 0.43 | 1.1 (0.4–2.7) | 0.91 |
| Galectin-3 (per ng/ml) | 1.01 (0.97–1.05) | 0.73    | – | – | – | – | – | – |
| High Galectin-3 (≥2.6 ng/ml) | 1.6 (0.7–3.6) | 0.26    | – | – | – | – | – | – |
| HbA1c > 70 mmol/mol (> 8.6%) | 2.6 (1.3–5.1) | 0.004    | 1.3 (0.6–3.0) | 0.47 | 1.3 (0.6–3.0) | 0.47 | 1.3 (0.6–3.0) | 0.48 |
| HDL-cholesterol      | 0.4 (0.2–1.0) | 0.056    | 1.2 (0.4–3.5) | 0.75 | 1.2 (0.4–3.5) | 0.75 | 1.4 (0.4–4.2) | 0.59 |
| Continuous subcutaneous insulin infusion | 0.2 (0.03–1.5) | 0.12    | – | – | – | – | – | – |
| Cardiovascular complications | 2.5 (0.6–10.1) | 0.19    | – | – | – | – | – | – |

\(^{a,b,c}\)Multiple logistic regression analyses (Backward: Wald); N = \(^{a,b,c}\)278; Nagelkerke R Square \(^{a,b,c}\)0.227/0.258; Hosmer and Lemeshow \(^{a,b,c}\)0.148/0.163/0.475. In model 1, anxiety and abdominal obesity are included as separate variables. In model 2, combinations of anxiety and abdominal obesity are included. In model 3, high Gal3BP (≥ 3.3 µg/ml) is replaced by continuous Gal3BP. For missing values, see Tables 1, 2.
TABLE 4 | Associations with high levels of HbA1c.

| HbA1 >70 mmol/mol (>8.6%) |
|--------------------------|
| COR (95% CI) | P-value | AOR (95% CI) | P-value* |
| Age (per year) | 0.99 (0.97–1.01) | 0.27 | 0.98 (0.95–1.0) | 0.051 |
| Diabetes duration (per year) | 0.99 (0.97–1.02) | 0.65 | – | – |
| Sex (women) | 1.5 (0.9–2.4) | 0.16 | 0.8 (0.4–1.5) | 0.49 |
| Alexithymia | 2.6 (1.3–5.1) | 0.004 | 1.2 (0.5–2.7) | 0.62 |
| Depression | 2.6 (1.2–5.6) | 0.015 | 2.9 (1.2–6.9) | 0.014 |
| Anxiety | 1.2 (0.7–2.0) | 0.52 | – | – |
| Abdominal obesity | 3.3 (1.7–6.2) | < 0.001 | 4.0 (2.0–8.1) | < 0.001 |
| High Gal3BP (≥ 3.3 µg/ml) | 3.0 (1.7–5.5) | < 0.001 | 2.8 (1.5–5.4) | 0.002 |
| High sCD163 (≥0.6 µg/ml) | 1.7 (0.9–3.2) | 0.081 | 1.3 (0.6–2.6) | 0.46 |
| High Galectin-3 (≥2.6 ng/ml) | 0.6 (0.2–1.3) | 0.17 | – | – |
| HDL-cholesterol | 0.5 (0.2–1.0) | 0.040 | 0.8 (0.4–2.0) | 0.69 |
| Continuous subcutaneous insulin infusion | 0.7 (0.3–1.9) | 0.53 | – | – |

*Multiple logistic regression analyses (Backward: Wald); N = 278; Nagelkerke R Square 0.166. Hosmer and Lemeshow 0.885. For missing values, see Tables 1, 2.

main alexithymia subfactor was difficulty identifying feelings (DIF), which was correlated with Gal3BP.

Alexithymia and Immunity
Gal3BP, which previously was linked to metabolic disturbances, cardiovascular disease and mortality (21, 22, 27), was the only immuno-inflammatory variable independently associated with alexithymia. Gal3BP is important as it has the potential to induce pro-inflammatory cytokines (21, 26). Higher levels of Gal3B has been demonstrated in people with diabetes mellitus compared to people without diabetes (21). In these T1D patients, there was an association between high Gal3BP levels and impaired glycemic control expressed as high HbA1c levels. In patients with previous myocardial infarction, high Gal3BP levels and diabetes mellitus were independently associated with increased risk for the development of angina pectoris or reinfarction (22). Gal3BP has been suggested as a novel important biomarker for cardiovascular risk assessment (22). To our knowledge, an association between alexithymia and Gal3BP has not previously been demonstrated.

Alexithymia and Depression
Depression is a clear risk factor for cardiovascular disease and all-cause mortality (38). The patients with alexithymia in this study had a very high prevalence of depression, which is in accordance with previous research (9, 14–16). Alexithymia has been suggested as a risk factor for depression even though alexithymic features seem to increase during depressive episodes (55, 56). Several immuno-inflammatory disturbances have been demonstrated in depressive states such as increased levels of galectin-3 and decreased soluble TWEAK (31, 32, 41, 43). Galectin-3 not only serves as a biomarker, but is also a contributor to cardiovascular disease and mortality (22, 24, 25).

Alexithymia and Metabolic Disturbances
Alexithymia has previously been linked to obesity and binge eating disorders (11). Obesity is a major risk factor for cardiovascular disease (13, 21, 34) and there is some evidence that anxiety contributes to cardiovascular disease (39). Anxiety and abdominal obesity were closely linked in this study, and these two factors combined were associated with alexithymia. One possible mechanism is that patients with alexithymia cannot discriminate between the unease caused by anxiety and the unease caused by hunger. Another possibility is that people with alexithymia cannot distinguish between symptoms of hypoglycaemia and anxiety. Difficulty in distinguishing between bodily sensations due to emotional arousal and due to other causes is a main characteristic of alexithymia (2). In both cases, the consequences of this particular alexithymia feature may be increased food intake with subsequent weight gain. Obesity might also cause anxiety, as patients with diabetes are regularly informed about the deleterious impact obesity may have on their health (34, 49).

The patients with and without alexithymia did neither differ by levels of blood pressure or s-lipids, nor by the prevalence of antihypertensive medication or lipid-lowering drugs usage, which differ from previous research (13).

Alexithymia and Life Style
Smoking habits and levels of physical activity didn’t differ between patients with and without alexithymia.

Potential Explanatory Mechanisms
As this study is a cross-sectional study, we cannot determine any causality. We will, however, discuss potential explanatory mechanisms. There is evidence from previous research that parts of the innate immune system which during the evolution were developed to fight pathogens, might be activated by environmental psychosocial stress or by the anticipation of perceived danger (43, 44). Persons with alexithymia may...
be inclined to anticipate danger, particularly if they during childhood were exposed to physical abuse, emotional neglect or other types of trauma, which are risk factors for alexithymia (5). According to previous research alexithymia is characterized by inflexible emotional dysregulation with dysfunctional emotional reactivity and prolonged emotional states (4), which potentially could trigger prolonged immune reactions in case of perceived or anticipated danger. The immune system acts in a coordinated way with the sympathetic nervous system and the HPA-axis (2, 3, 43). The increased baseline sympathetic activity or the disturbances of the HPA axis observed in alexithymia (2, 3), may trigger the immune system with increased levels of Gal3BP. The increased Gal3BP levels are deleterious for patients with T1D as Gal3BP induces a number of pro-inflammatory cytokines (21). Increased levels of Gal3BP contribute to metabolic disturbances (27), and increased Gal3BP levels are risk factors for cardiovascular disease and all-cause mortality (21, 22).

Blood glucose levels also increase by activation of the stress system (57), which may contribute to the demonstrated increased HbA1c levels.

**Future Research**

In future research it would be of interest to explore the impact of alexithymia, Gal3BP and depression on cardiovascular complications in a longitudinal study. Another subject for research would be to explore whether therapies aiming at increased emotional awareness could ameliorate alexithymia features (51). At a molecular level it would be of interest to further explore stress, alexithymia, depression, sterile inflammation and danger-associated molecular patterns (DAMP) (44).

**Strengths and Limitations of the Study**

Strengths of our study are that patients with severe comorbidities such as cancer, severe autoimmune disorders, hepatic failure, end-stage renal disease, psychotic and bipolar disorders were excluded as these disorders, or medication for these disorders, may have impact on the immune system (26, 27). We controlled for relevant variables previously linked to cardiovascular disease and mortality. The logistic regression models were elaborated for the associations, and calibrated and validated for goodness of fit with the data variables. The included variables were checked for multicollinearity, and no significant evidence of multicollinearity was demonstrated. ROC analyses were performed and the area under the curve was only significant for Gal3BP and alexithymia, not for depression. Multiple linear regression analysis was performed and alexithymia was associated with log transformed Gal3BP, which was not the case for depression. Altogether, these analyses support the result of the multiple logistic regression analyses, Gal3BP and depression were independently associated with alexithymia. Finally, precise ELISA techniques were used and showed low intra-assay coefficients of variation for Gal3BP, sCD163 and galectin-3 (31, 47, 48).

Cross-sectional studies have limitations as causality cannot be confirmed. Only a limited number of patients with cardiovascular disease participated in the study, so an association between Gal3BP and cardiovascular complications could neither be confirmed nor excluded. The $P$-value was quite low, which could indicate a type-2 error. Depression, anxiety and alexithymia were only assessed by self-report instruments, not by a structured interview. TAS-20 is, however, extensively used in research, and evidence collected for 26 years supports that the scale adequately measures the alexithymia construct (3, 8, 9, 11, 14, 17, 18, 52). HADS has also shown high validity for assessing symptoms of depression and anxiety both at an individual and a collective level (53).

**CONCLUSIONS**

Gal3BP, depression and younger age were independently associated with alexithymia. The patients with alexithymia also had higher levels of HbA1c, and higher prevalence of abdominal obesity and anxiety, but these factors were not independently linked to alexithymia. The findings of this study contribute to the understanding of the complex processes which may contribute to the development of cardiovascular disease in patients with T1D and alexithymia.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Regional Ethical Review Board of Linköping University, Linköping, Sweden (Registration no. M120-07, T89-08). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

RS, JD, MH, and EM participated as investigators and reviewed, edited, and approved the final version of the manuscript. RS contributed with his knowledge of psychology and initiated the research group’s interest in the health implications of alexithymia. JD and MH contributed with their knowledge of immunology, performed the analyses of the immunologically active variables, and they take the full responsibility for these analyses. EM integrated the knowledge of psychology, clinical medicine and immunology, performed the statistical analysis, is the guarantor of this work and, as such, had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

FUNDING

This research was supported by the Southern Healthcare Region, Lund, Sweden; by the Research Council of South Eastern Sweden (FORSS), Linköping, Sweden (708401); and by the Research and Development Fund of Health Care, Region Kronoberg, Växjö, Sweden (936138). The funding sources were not involved in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.

ACKNOWLEDGMENTS

The authors are grateful to Anna Lindgren, Ph.D. at the Department of Mathematical Statistics, Lund University, Lund, Sweden, for her statistical skills.

REFERENCES

1. Taylor GJ. Alexithymia: concept, measurement, and implications for treatment. Am J Psychiatry. (1984) 141:725–32. doi: 10.1176/ajp.141.6.725
2. Guilbaud O, Corsos M, Hjalmarsson L, Loas G, Jeammet P. Is there a psychoneuromunological pathway between alexithymia and immunity? Immune and physiological correlates of alexithymia. Biomed Pharmacother. (2003) 57:292–5. doi: 10.1016/S0753-3322(03)00085-4
3. Reed RG, Raison CL. Stress and the immune system. In: Esser C, editor. Environmental Influences on the Immune System. Vienna: Springer Vienna. (2016). p. 97–126. doi: 10.1007/978-3-7091-1890-0_5
4. Panayiotou G, Panteli M, Vlemminx E. Adaptive and maladaptive emotion processing and regulation, and the case of alexithymia. Cogn Emot. (2019) 35:488–99. doi: 10.1080/02699931.2019.1671322
5. Güleç MY, Altintaş M, Inanç L, Bezgin ÇH, Koca EK, Güleç H. Effects of childhood trauma on somatization in major depressive disorder: The role of alexithymia. J Affect Disord. (2013) 146:137–41. doi: 10.1016/j.jad.2012.06.033
6. Goerlich KS. The multifaceted nature of alexithymia – A neuroscientific perspective. Front Psychol. (2018) 9:1614. doi: 10.3389/fpsyg.2018.01614
7. Meza-Concha N, Arancibia M, Salas F, Behar R, Salas G, Silva H, et al. Towards a neurobiological understanding of alexithymia. Medwave. (2017) 17:e0960. doi: 10.5867/medwave.2017.04.0960
8. Tolmunen T, Lehto SM, Heliste M, Kurl S, Kauhanen J. Alexithymia is associated with increased cardiovascular mortality in middle-aged Finnish men. Psychosom Med. (2010) 72:187–91. doi: 10.1097/PSY.0b013e3181e5d00
9. Valkamo M, Hintikka J, Honkalampi K, Niskanen L, Koivumaa-Honkanen H, Viinamaki H. Alexithymia in patients with coronary heart disease. J Psychosom Res. (2001) 50:125–30. doi: 10.1016/S0022-3999(00)00209-9
10. Chatti L, Bitsios P, Solidaki E, Christou I, Kyrilaki E, Sfakianni M, et al. Type 1 diabetes is associated with alexithymia in nondepressed, non-mentally diabetic patients: a case-control study. J Psychosom Res. (2009) 67:307–13. doi: 10.1016/j.jpsychores.2009.04.011
11. Pinna F, Lai L, Pirarba S, Orru W, Velluzzi F, Loviselli A, et al. Obesity, alexithymia and psychopathology: a case-control study. Eat Weight Disord. (2011) 16:e164–70. doi: 10.32757/57509
12. Melin EO, Svensson R, Thunander M, Hillman M, Thulesius HO, Landin-Olsson M. Gender, alexithymia and physical inactivity associated with abdominal obesity in type 1 diabetes mellitus: a cross sectional study at a secondary care hospital diabetes clinic. BMC Obes. (2017) 4:21. doi: 10.1186/s40608-017-0157-1
13. Alju’a A, Malas O, Urieta P, Worner F, Balada F. Biological correlates of the Toronto Alexithymia Scale (TAS-20) in cardiovascular disease and healthy community subjects. Physiol Behav. (2020) 227:113151. doi: 10.1016/j.physbeh.2020.113151
14. Honkalampi K, Hintikka J, Tanskanen A, Lehtonen J, Viinamaki H. Depression is strongly associated with alexithymia in the general population. J Psychosom Res. (2000) 48:99–104. doi: 10.1016/S0022-3999(99)00835-8
15. Melin EO, Thunander M, Svensson R, Landin-Olsson M, Thulesius HO. Depression, obesity and smoking were independently associated with inadequate glycemic control in patients with type 1 diabetes. Eur J Endocrinol. (2013) 168:861–9. doi: 10.1530/EJE-13-0137
16. Bergman MA, Vissers CTWAM, Collard RM, van Eijndhoven P, Schene AH, Vrijen B. The effect of alexithymia on attentional bias toward emotional stimuli in depression: an eye-tracking study. Front Psychiatry. (2021) 11:1597. doi: 10.3389/fpsyg.2020.06946
17. Karukivi M, Hautala I, Kaleva O, Haapasalo-Pesu KM, Liuksla PR, Joukamaa M, et al. Alexithymia is associated with anxiety among adolescents. J Affect. Disord. (2010) 125:383–7. doi: 10.1016/j.jad.2010.02.126
18. Sağö D, Babiç G, Bacić Z, Filipić I. Panic disorder as unthinkable emotions: alexithymia in panic disorder, a croatian cross-sectional study. Front Psychiatry. (2020) 11:466. doi: 10.3389/fpsyt.2020.00466
19. Back M, Yurdagul A, Tabas I, O¨ ren K, Kovaren PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. (2019) 16:389–406. doi: 10.1038/s41569-019-0169-2
20. Nguyen MT, Fernando S, Schwarz N, Tan J, Bursill CA, Paltis P. Inflammation as a therapeutic target in atherosclerosis. J Clin Med. (2019) 8:1109. doi: 10.3390/jcm8081109
21. Gleissner CA, Erbel C, Linden F, Domschke G, Akhavanpoor M, Helmes CM, et al. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: insights from the LURIC study. Atherosclerosis. (2017) 260:121–9. doi: 10.1016/j.atherosclerosis.2017.03.031
22. Gagno G, Padoan L, Stener E, Beleut A, Ziberna F, Hliche C, et al. Galectin-3 and Galectin 3 binding protein improve the risk stratification after myocardial infarction. J Clin Med. (2019) 8:570. doi: 10.3390/jcm8050570
23. Ilter A, Orem C, Yucesan FB, Sahin M, Hosoglu Y, Kurumahmutoglu E, et al. Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease. *Int J Clin Exp Med.* (2015) 8:3934.

24. Sharma UC, Pokharel S, van Brekel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. *Circulation.* (2004) 110:3121–8. doi: 10.1161/01.CIR.0000147181.65298.4D

25. Kusaka H, Yamamoto E, Hirata Y, Fujisue K, Tokitsu T, Sugamura K, et al. Clinical significance of plasma galectin-3 in patients with coronary artery disease. *Int J Cardiol.* (2015) 201:532–4. doi: 10.1016/j.ijcard.2015.08.099

26. Xu G, Xia Z, Deng F, Liu W, Wang Q, Yu Y, et al. Inducible LGLASBP90K activates antiviral innate immune responses by targeting TRAF6 and TRAF3 complex. *PLoS Pathog.* (2019) 15:e1008002. doi: 10.1371/journal.ppat.1008002

27. Kamada Y, Morishita K, Koseki M, Nishida M, Asuka T, Naito Y, et al. Serum Mac-2 binding protein levels associate with metabolic parameters and predict liver fibrosis progression in subjects with fatty liver disease: a 7-year longitudinal study. *Nutrients.* (2020) 12:1770. doi: 10.3390/nu12061770

28. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SA, et al. Identification of the haemoglobin scavenger receptor. *Nature.* (2001) 409:198–201. doi: 10.1038/35051594

29. Møller HJ. Soluble CD163. *Scaend J Clin Lab Invest.* (2012) 72:1–13. doi: 10.3109/030653513.2012.626688

30. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. *Immunol Rev.* (2009) 230:160–71. doi: 10.1111/j.1600-065X.2009.00794.x

31. Melin EO, Dereke J, Thunander M, Hillman M. Depression in type 1 diabetes was associated with high levels of circulating galectin-3. *Endocr Connect.* (2017) 8:1819–28. doi: 10.1530/EC-17-0108

32. King DR, Salako DC, Arthur-Bentil SK, Rubin AE, Italiya JB, Tan JS, et al. Soluble CD163 was linked to galectin-3, diabetic retinopathy and antidepressants in type 1 diabetes. *Endocr Connect.* (2018) 7:1343–53. doi: 10.1530/EC-18-0336

33. Melin EO, Thunander M, Landin-Olsson M, Hillman M, Thulesius HO. Abdominal obesity in type 1 diabetes associated with gender, cardiovascular risk factors and complications, and difficulties achieving treatment targets: a cross sectional study at a secondary care diabetes clinic. *BMC Obes.* (2018) 5:15. doi: 10.1186/s40608-018-0193-5

34. Bagby RM, Parker JD, Taylor GJ. The twenty-item Toronto Alexithymia Scale–1. Item selection and cross-validation of the factor structure. *J Psychosom Res.* (1994) 38:23–32. doi: 10.1016/0022-3999(94)90005-1

35. Bagby RM, Taylor GJ, Parker JD. The Twenty-item Toronto Alexithymia Scale–II. Convergent, discriminant, and concurrent validity. *J Psychosom Res.* (1994) 38:33–40. doi: 10.1016/0022-3999(94)90006-X

36. Bagby RM, Parker JD, Taylor GJ. Twenty-five years with the 20-item Toronto Alexithymia Scale. *J Psychosom Res.* (2020) 131:109940. doi: 10.1016/j.jpsychores.2020.109940

37. Bocéran C, Dupret E. A validation study of the Hospital Anxiety and Depression Scale (HADS) in a large sample of French employees. *BMC Psychiatry.* (2014) 14:11–11. doi: 10.1186/s12888-014-0354-0

38. Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: Logistic regression. *Perspect Clin Res.* (2017) 8:148–51. doi: 10.4103/picr.PICR_123_17

39. Tolmumen T, Heliste M, Lehto SM, Hintikka J, Honkalampi K, Kauhanen J. Stability of alexithymia in the general population: an 11-year follow-up. *Psychother Psychosom.* (2015) 84:129–41. doi: 10.1159/000353076

40. Luminet O, Bagby RM, Taylor GJ. An evaluation of the absolute and relative stability of alexithymia in patients with major depression. *Psychother Psychosom.* (2001) 70:254–60. doi: 10.1159/000056263

41. Romero ML, Butler LC. Endocrinology of stress. *Int J Comp Psychol.* (2007) 20:89–95.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Melin, Svensson, Dereke and Hillman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.